Spring Creek HealthCare Systems, Inc. Announces Agreement for Its DelRX Pharmaceutical Corp.

Spring Creek (OTCBB: SCRK) announces that its wholly owned subsidiary, DelRX Pharmaceutical Corp., has signed an agreement licensing its proprietary drug delivery system to TheraBiogen, Inc., an affiliate company. The DelRX system delivers homeopathics and critical therapeutic drugs through the oral mucosa of the buccal cavity. Jan E. Chason, CFO of Spring Creek, says "We have been nurturing this program for some time and are very pleased to sign this licensing agreement. The DelRX delivery platform will enable a product line extension for TheraBiogen allowing them to meet consumer preferences for nasal or oral delivery." The two companies will begin product implementation as soon as practicable.

TheraBiogen, Inc.'s CEO, Kelly T. Hickel, says, "We are very excited to add another product delivery platform to our TheraMax® product line. Our consumer customers have shown a desire to be able to choose the delivery platform to meet their personal preferences. This allows us to reach additional consumers as we continue the national launch of our TheraMax® products."

DelRx has proprietary platform drug delivery technology for transmucosal administration of large molecule drugs as a liquid dispersion, e.g., peptides like insulin, monoclonal antibodies, hormones, vaccines and other proteins as well as homeopathic formulations. These macro-molecular drugs cannot be administered orally and are injected, usually with a needle and syringe or by intravenous infusion. If DelRx's oral drug delivery technology provides comparable clinical efficacy to injections, then this has the potential to offer significant improvements in the quality of life (pain free, needle free therapy), with reduced side effects for diabetics and other patients.